GlassScriptPhysician profile
William Edward Pollock
NPI 1881867919
$4,040.58
in general payments reported to CMS, 2019-2025
36 companies · $746 in 2025
The $746 reported for 2025 was more than what 75% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,245 · 2022: $677 · 2023: $637 · 2024: $736 · 2025: $746.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,119.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,118.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $503.75 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $428.16 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $415.52 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Teva Pharmaceuticals USA, INC. | $352.52 | 2021-2023 | Ajovy |
| Lilly USA, LLC | $246.80 | 2021-2025 | Jardiance, Mounjaro, Emgality |
| Amgen INC. | $230.04 | 2023-2025 | Otezla, Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $198.17 | 2021-2024 | Jardiance |
| Glaxosmithkline, LLC. | $169.29 | 2021-2025 | Shingrix, Arexvy |
| Pfizer INC. | $154.48 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $128.92 | 2021-2023 | Steglatro, Belsomra |
| Astellas Pharma US INC | $119.07 | 2023-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $103.65 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $95.92 | 2022-2023 | |
| Biohaven Pharmaceuticals, INC. | $90.61 | 2021 | |
| Sumitomo Pharma America, INC. | $90.13 | 2025 | Gemtesa, Myfembree |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $81.43 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $63.75 | 2024-2025 | Xifaxan |
| Biohaven Pharmaceutical Holding Company LTD. | $59.57 | 2022 | |
| Si-Bone, INC. | $49.89 | 2023-2024 | |
| E.R. Squibb & Sons, L.L.C. | $44.21 | 2021-2022 | |
| Edwards Lifesciences Corporation | $42.91 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Sunovion Pharmaceuticals INC. | $39.96 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $38.88 | 2024 | |
| Bausch Health US, LLC | $37.32 | 2021-2022 | |
| Ardelyx, INC. | $31.99 | 2025 | Ibsrela |
| Otsuka America Pharmaceutical, INC. | $28.75 | 2024 | Nuedexta |
| Tonix Medicines, INC. | $23.65 | 2025 | Tonmya |
| Evoke Pharma, INC. | $23.31 | 2025 | |
| Hologic Sales and Service, LLC | $21.48 | 2023 | Thinprep 2000 Processor |
| Antares Pharma, INC. | $21.20 | 2023 | Tlando, Nocdurna, Xyosted |
| Phadia US INC. | $19.87 | 2023 | Immunocap |
| Ucb, INC. | $19.21 | 2022 | |
| Phathom Pharmaceuticals, INC. | $18.20 | 2024 | Voquezna |
| Xeris Pharmaceuticals, INC. | $17.52 | 2021 | |
| Almatica Pharma LLC | $16.83 | 2021 | |
| Exact Sciences Corporation | $13.62 | 2025 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Pollock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.